JP2020514363A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020514363A5 JP2020514363A5 JP2019550705A JP2019550705A JP2020514363A5 JP 2020514363 A5 JP2020514363 A5 JP 2020514363A5 JP 2019550705 A JP2019550705 A JP 2019550705A JP 2019550705 A JP2019550705 A JP 2019550705A JP 2020514363 A5 JP2020514363 A5 JP 2020514363A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- amino acid
- acid sequence
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024009215A JP2024050684A (ja) | 2017-03-17 | 2024-01-25 | 腫瘍特異的細胞枯渇のためのＦｃ最適化抗ＣＤ２５ |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17161717 | 2017-03-17 | ||
| EP17161717.8 | 2017-03-17 | ||
| GBGB1710879.6A GB201710879D0 (en) | 2017-07-06 | 2017-07-06 | Methods and compounds for tumour-specific cell depletion |
| GB1710879.6 | 2017-07-06 | ||
| GBGB1714429.6A GB201714429D0 (en) | 2017-09-07 | 2017-09-07 | Compounds and methods for tumour-specific cell depletion |
| GB1714429.6 | 2017-09-07 | ||
| PCT/EP2018/056312 WO2018167104A1 (en) | 2017-03-17 | 2018-03-13 | Fc-optimized anti-cd25 for tumour specific cell depletion |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024009215A Division JP2024050684A (ja) | 2017-03-17 | 2024-01-25 | 腫瘍特異的細胞枯渇のためのＦｃ最適化抗ＣＤ２５ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020514363A JP2020514363A (ja) | 2020-05-21 |
| JP2020514363A5 true JP2020514363A5 (https=) | 2021-04-30 |
Family
ID=61655786
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019550705A Pending JP2020514363A (ja) | 2017-03-17 | 2018-03-13 | 腫瘍特異的細胞枯渇のためのＦｃ最適化抗ＣＤ２５ |
| JP2024009215A Pending JP2024050684A (ja) | 2017-03-17 | 2024-01-25 | 腫瘍特異的細胞枯渇のためのＦｃ最適化抗ＣＤ２５ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024009215A Pending JP2024050684A (ja) | 2017-03-17 | 2024-01-25 | 腫瘍特異的細胞枯渇のためのＦｃ最適化抗ＣＤ２５ |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US11879014B2 (https=) |
| EP (1) | EP3596123B1 (https=) |
| JP (2) | JP2020514363A (https=) |
| KR (1) | KR20190130137A (https=) |
| CN (1) | CN110869388B (https=) |
| AU (1) | AU2018233976B2 (https=) |
| BR (1) | BR112019017017A2 (https=) |
| CA (1) | CA3056506A1 (https=) |
| CL (1) | CL2019002624A1 (https=) |
| CR (1) | CR20190477A (https=) |
| DK (1) | DK3596123T3 (https=) |
| ES (1) | ES2975063T3 (https=) |
| FI (1) | FI3596123T3 (https=) |
| HR (1) | HRP20240469T1 (https=) |
| HU (1) | HUE065999T2 (https=) |
| IL (1) | IL269081B1 (https=) |
| LT (1) | LT3596123T (https=) |
| MX (1) | MX2019010974A (https=) |
| MY (1) | MY208220A (https=) |
| PE (1) | PE20191812A1 (https=) |
| PL (1) | PL3596123T3 (https=) |
| RS (1) | RS65351B1 (https=) |
| SG (1) | SG11201908578YA (https=) |
| SI (1) | SI3596123T1 (https=) |
| WO (1) | WO2018167104A1 (https=) |
| ZA (1) | ZA201904980B (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11371066B2 (en) | 2015-07-13 | 2022-06-28 | Modular Genetics, Inc. | Generation of acyl alcohols |
| US11879014B2 (en) | 2017-03-17 | 2024-01-23 | Tusk Therapeutics Ltd. | Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody |
| KR102909650B1 (ko) * | 2018-03-13 | 2026-01-08 | 터스크 테라퓨틱스 리미티드 | 종양 특이적 세포 고갈에 대한 항-cd25 |
| CA3120096A1 (en) | 2018-11-14 | 2020-05-22 | Rubryc Therapeutics, Inc. | Cd25 antibodies |
| EP3880698A4 (en) | 2018-11-14 | 2022-11-30 | RubrYc Therapeutics, Inc. | MANIPULATED CD25 POLYPEPTIDES AND USES THEREOF |
| EP3972997A1 (en) * | 2019-05-20 | 2022-03-30 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Novel anti-cd25 antibodies |
| PL3932949T3 (pl) * | 2019-06-10 | 2025-11-24 | Shandong Boan Biotechnology Co., Ltd. | Przeciwciało anty-cd25 i jego zastosowanie |
| BR112022020521A2 (pt) | 2020-04-10 | 2023-03-07 | Rakuten Medical Inc | Compostos de corante ftalocianina, conjugados e métodos de uso dos mesmos |
| WO2021228218A1 (zh) | 2020-05-14 | 2021-11-18 | 江苏恒瑞医药股份有限公司 | 抗cd25抗体、其抗原结合片段及其医药用途 |
| US11124568B1 (en) * | 2020-08-19 | 2021-09-21 | Vitruviae LLC | CD3/CD25 antibodies for neuro-immune diseases |
| EP4247497A1 (en) * | 2020-11-20 | 2023-09-27 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Anti-cd25 antibodies |
| WO2022106663A1 (en) * | 2020-11-20 | 2022-05-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-cd25 antibodies |
| WO2022117572A2 (en) | 2020-12-02 | 2022-06-09 | Oncurious Nv | An ltbr agonist in combination therapy against cancer |
| WO2022182483A1 (en) * | 2021-02-02 | 2022-09-01 | Rakuten Medical, Inc. | Methods for local and systemic treatment of cancers, tumors and tumor cells |
| KR20230154012A (ko) | 2021-03-01 | 2023-11-07 | 에프. 호프만-라 로슈 아게 | 신규 바이오마커 및 이의 용도 |
| TW202319400A (zh) | 2021-09-02 | 2023-05-16 | 瑞士商赫孚孟拉羅股份公司 | 用於治療aml之抗體 |
| US20250257141A1 (en) | 2022-04-26 | 2025-08-14 | Hoffmann-La Roche Inc. | Combination therapy for the treatment of cancer comprising a fas axis antagonist and a t-reg cell depleting agent antagonist |
| CN115181182B (zh) * | 2022-06-13 | 2024-03-29 | 南京融捷康生物科技有限公司 | 一种人源化的抗cd25的单域抗体及其应用 |
| CA3260932A1 (en) * | 2022-06-30 | 2024-01-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | CD25-SPECIFIC ANTIBODIES AND THEIR USES |
| CN119451978A (zh) | 2022-07-01 | 2025-02-14 | 神经基因治疗公司 | Neo-2/15变体及其用于优先刺激T调节细胞的用途 |
| WO2024088987A1 (en) | 2022-10-26 | 2024-05-02 | F. Hoffmann-La Roche Ag | Combination therapy for the treatment of cancer |
| CN118240080A (zh) * | 2022-12-22 | 2024-06-25 | 深圳市福元生物科技有限公司 | 一种cd25单域抗体、人源化抗体、及制备方法 |
| EP4662238A1 (en) | 2023-02-06 | 2025-12-17 | F. Hoffmann-La Roche AG | Combination therapy and uses thereof |
| CN116087499B (zh) * | 2023-02-20 | 2023-10-31 | 深圳裕康医学检验实验室 | 一种癌样本的染色方法及试剂盒 |
| CN120314588B (zh) * | 2025-05-21 | 2025-10-17 | 成都蓉生药业有限责任公司 | 一种人免疫球蛋白抗体依赖性细胞介导的吞噬作用生物学活性的检测方法和检测试剂盒 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4208479A (en) | 1977-07-14 | 1980-06-17 | Syva Company | Label modified immunoassays |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化ｂ−ｂ１０ |
| US7438907B2 (en) | 2002-11-15 | 2008-10-21 | Genmab A/S | Human monoclonal antibodies against CD25 |
| WO2004063355A2 (en) | 2003-01-10 | 2004-07-29 | Protein Design Labs, Inc. | Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer |
| GB0409799D0 (en) * | 2004-04-30 | 2004-06-09 | Isis Innovation | Method of generating improved immune response |
| GB0507696D0 (en) | 2005-04-15 | 2005-05-25 | Novartis Ag | Organic compounds |
| WO2008002933A2 (en) | 2006-06-26 | 2008-01-03 | Macrogenics, Inc. | Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof |
| CA2656700A1 (en) | 2006-07-06 | 2008-01-10 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Compositions and methods for enhancing the efficacy of il-2 mediated immune responses |
| AR062435A1 (es) | 2006-08-18 | 2008-11-05 | Xoma Technology Ltd | Anticuerpo especifico prlr (receptor de prolactina) y sus usos |
| RU2391401C2 (ru) | 2008-02-12 | 2010-06-10 | Общество с ограниченной ответственностью "Лаборатория клеточного мониторинга" | СПОСОБ ПОЛУЧЕНИЯ ПОПУЛЯЦИИ CD4+CD25+Foxp3+ Т-ЛИМФОЦИТОВ ЧЕЛОВЕКА ex vivo, СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ |
| DK2356270T3 (da) | 2008-11-07 | 2016-12-12 | Fabrus Llc | Kombinatoriske antistofbiblioteker og anvendelser deraf |
| SG178925A1 (en) | 2009-09-22 | 2012-04-27 | Volker Sandig | Process for producing molecules containing specialized glycan structures |
| PL3498730T3 (pl) * | 2009-12-21 | 2026-04-07 | Regeneron Pharmaceuticals, Inc. | Humanizowane myszy fc gamma r |
| AR079944A1 (es) | 2010-01-20 | 2012-02-29 | Boehringer Ingelheim Int | Anticuerpo neutralizante de la actividad de un anticoagulante |
| MX349662B (es) | 2010-07-22 | 2017-08-08 | Univ California | Anticuerpos de antigenos antitumorales y metodos de uso. |
| EP2970488A2 (en) | 2013-03-15 | 2016-01-20 | AbbVie Biotechnology Ltd | Anti-cd25 antibodies and their uses |
| EP2970486B1 (en) * | 2013-03-15 | 2018-05-16 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
| MX2015012563A (es) | 2013-03-15 | 2016-10-26 | Abbvie Biotechnology Ltd | Anticuerpos anti-cd25 y sus usos. |
| GB2526139A (en) | 2014-05-15 | 2015-11-18 | Biolnvent Internat Ab | Medicaments, uses and methods |
| US20170204154A1 (en) | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| KR20220032642A (ko) | 2016-04-07 | 2022-03-15 | 캔써 리서치 테크놀로지 리미티드 | 종양 특이적 세포 고갈을 위한 항 cd25 fc 감마 수용체 이중특이적 항체 |
| US11077172B2 (en) | 2016-11-08 | 2021-08-03 | Delinia, Inc. | IL-2 variants for the treatment of psoriasis |
| US11879014B2 (en) | 2017-03-17 | 2024-01-23 | Tusk Therapeutics Ltd. | Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody |
| MX2020008768A (es) | 2018-03-13 | 2020-10-08 | Tusk Therapeutics Ltd | Agentes anticuerpos anti-cd25. |
-
2018
- 2018-03-03 US US16/494,962 patent/US11879014B2/en active Active
- 2018-03-13 RS RS20240376A patent/RS65351B1/sr unknown
- 2018-03-13 LT LTEPPCT/EP2018/056312T patent/LT3596123T/lt unknown
- 2018-03-13 HR HRP20240469TT patent/HRP20240469T1/hr unknown
- 2018-03-13 PE PE2019001847A patent/PE20191812A1/es unknown
- 2018-03-13 PL PL18711313.9T patent/PL3596123T3/pl unknown
- 2018-03-13 MX MX2019010974A patent/MX2019010974A/es unknown
- 2018-03-13 SG SG11201908578Y patent/SG11201908578YA/en unknown
- 2018-03-13 ES ES18711313T patent/ES2975063T3/es active Active
- 2018-03-13 BR BR112019017017-0A patent/BR112019017017A2/pt unknown
- 2018-03-13 EP EP18711313.9A patent/EP3596123B1/en active Active
- 2018-03-13 AU AU2018233976A patent/AU2018233976B2/en active Active
- 2018-03-13 CA CA3056506A patent/CA3056506A1/en active Pending
- 2018-03-13 SI SI201831085T patent/SI3596123T1/sl unknown
- 2018-03-13 HU HUE18711313A patent/HUE065999T2/hu unknown
- 2018-03-13 FI FIEP18711313.9T patent/FI3596123T3/fi active
- 2018-03-13 WO PCT/EP2018/056312 patent/WO2018167104A1/en not_active Ceased
- 2018-03-13 CR CR20190477A patent/CR20190477A/es unknown
- 2018-03-13 MY MYPI2019005313A patent/MY208220A/en unknown
- 2018-03-13 CN CN201880018976.8A patent/CN110869388B/zh active Active
- 2018-03-13 KR KR1020197030283A patent/KR20190130137A/ko not_active Ceased
- 2018-03-13 DK DK18711313.9T patent/DK3596123T3/da active
- 2018-03-13 JP JP2019550705A patent/JP2020514363A/ja active Pending
-
2019
- 2019-07-29 ZA ZA2019/04980A patent/ZA201904980B/en unknown
- 2019-09-02 IL IL269081A patent/IL269081B1/en unknown
- 2019-09-13 CL CL2019002624A patent/CL2019002624A1/es unknown
-
2024
- 2024-01-25 JP JP2024009215A patent/JP2024050684A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020514363A5 (https=) | ||
| AU2019406453B2 (en) | Bifunctional molecule directed against human PD-1 | |
| JP7397055B2 (ja) | Ｃｄ１３７及びｏｘ４０に結合する抗体分子 | |
| JP7575100B2 (ja) | 免疫細胞活性化のための二重特異性抗体 | |
| JP2024050684A (ja) | 腫瘍特異的細胞枯渇のためのＦｃ最適化抗ＣＤ２５ | |
| ES2980623T3 (es) | Anticuerpos de unión a CD3 | |
| CN109641049B (zh) | Cd3结合抗体 | |
| JP7225135B2 (ja) | 腫瘍特異的細胞枯渇のための化合物及び方法 | |
| JP2019513725A5 (https=) | ||
| JP2020521759A (ja) | 免疫トレランスを調節するための多機能性の抗体−リガンド・トラップ | |
| IL323895A (en) | Bifunctional anti-pd-1/il-7 molecule | |
| IL259495B2 (en) | Antibodies and methods for using them | |
| JP2017511379A (ja) | アゴニストまたはアンタゴニスト性を誘発する修飾されたＩｇＧ２ドメインを含む修飾された抗体及びその使用 | |
| CN114269785A (zh) | 免疫刺激性多聚体结合分子 | |
| KR20180037924A (ko) | 항-ctla-4 항체 및 이의 사용 방법 | |
| JP7680208B2 (ja) | 抗ｃｄ２７抗体およびその使用 | |
| JP2016513467A5 (https=) | ||
| JP2022553129A (ja) | ポリオウイルス受容体（ｐｖｒ）に対する抗体およびその使用 | |
| KR20210110818A (ko) | Rank 길항제 및 이에 대한 용도 | |
| US20250002600A1 (en) | Multispecific binding agents against pd-l1 and cd137 in combination therapy | |
| CA3259108A1 (en) | Attenuated Anti-PD1-IL2 Immunoconjugates and Their Uses | |
| JP7284759B2 (ja) | 抗ｃｄ４０抗体およびその使用 | |
| KR20250089513A (ko) | 암 치료에 있어서의 pd-1 시그널 저해제와의 조합에 의한 항cldn4-항cd137 이중특이성 항체의 사용 | |
| JPWO2022072601A5 (https=) | ||
| CN118339183A (zh) | 组合中针对pd-l1和cd137的多特异性结合剂 |